[go: up one dir, main page]

AR124310A1 - INMUNOCITOQUINA PARA ACTIVAR EL RECEPTOR IL-10Ra HUMANO Y SU USO - Google Patents

INMUNOCITOQUINA PARA ACTIVAR EL RECEPTOR IL-10Ra HUMANO Y SU USO

Info

Publication number
AR124310A1
AR124310A1 ARP210103441A ARP210103441A AR124310A1 AR 124310 A1 AR124310 A1 AR 124310A1 AR P210103441 A ARP210103441 A AR P210103441A AR P210103441 A ARP210103441 A AR P210103441A AR 124310 A1 AR124310 A1 AR 124310A1
Authority
AR
Argentina
Prior art keywords
immunocytokine
human
receptor
methods
pharmaceutical compositions
Prior art date
Application number
ARP210103441A
Other languages
English (en)
Inventor
Aleksey Vladimirovich Kononov
Iuliia Viktorovna Evdokimovskaia
Iana Andreevna Smirnova
Stanislav Rudolfovich Evdokimov
Elena Sergeevna Kolosova
Sergei Andreevich Ageev
Vladimir Sergeevich Tsympilov
Valery Vladimirovich Solovyev
Pavel Andreevich Iakovlev
Dmitry Valentinovich Morozov
Original Assignee
Joint Stock Company “Biocad”
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2020140807A external-priority patent/RU2810750C2/ru
Application filed by Joint Stock Company “Biocad” filed Critical Joint Stock Company “Biocad”
Publication of AR124310A1 publication Critical patent/AR124310A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere al campo de la biotecnología y la medicina, en particular a una inmunocitoquina para activar el receptor IL-10Ra humano. La invención se refiere además a ácidos nucleicos que codifican dicha inmunocitoquina, vectores de expresión, células huésped y métodos para producirlos, métodos para producir la inmunocitoquina, composiciones farmacéuticas que comprenden la inmunocitoquina mencionada, composiciones farmacéuticas que comprenden la inmunocitoquina mencionada y otros compuestos terapéuticamente activos, métodos para tratar una enfermedad oncológica y los usos de la inmunocitoquina o de las composiciones farmacéuticas de la misma para tratar una enfermedad oncológica. Reivindicación 1: Una inmunocitoquina aislada para activar el receptor IL-10Ra humano, que comprende un complejo homodimérico basado en IL-10 y fragmento Fc de IgG1 humana, en el que el monómero basado en IL-10 y fragmento Fc de IgG1 humana comprende la secuencia de aminoácidos de SEQ ID Nº 1.
ARP210103441A 2020-12-10 2021-12-10 INMUNOCITOQUINA PARA ACTIVAR EL RECEPTOR IL-10Ra HUMANO Y SU USO AR124310A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2020140807A RU2810750C2 (ru) 2020-12-10 Иммуноцитокин для активации IL-10Rα рецептора человека и его применение

Publications (1)

Publication Number Publication Date
AR124310A1 true AR124310A1 (es) 2023-03-15

Family

ID=81973601

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210103441A AR124310A1 (es) 2020-12-10 2021-12-10 INMUNOCITOQUINA PARA ACTIVAR EL RECEPTOR IL-10Ra HUMANO Y SU USO

Country Status (19)

Country Link
US (1) US20240034764A1 (es)
EP (1) EP4259644A4 (es)
JP (1) JP2023553934A (es)
KR (1) KR20230118919A (es)
CN (1) CN117120461A (es)
AR (1) AR124310A1 (es)
AU (1) AU2021398529A1 (es)
CA (1) CA3201656A1 (es)
CL (1) CL2023001677A1 (es)
CO (1) CO2023007563A2 (es)
CR (1) CR20230243A (es)
EC (1) ECSP23043458A (es)
IL (1) IL303501A (es)
MA (1) MA61003B1 (es)
MX (1) MX2023006830A (es)
PE (1) PE20241070A1 (es)
TW (1) TW202237631A (es)
UY (1) UY39562A (es)
WO (1) WO2022124950A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2882774B1 (en) * 2012-08-08 2018-10-03 Roche Glycart AG Interleukin-10 fusion proteins and uses thereof
US9546203B2 (en) * 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
JP2017506075A (ja) * 2014-02-06 2017-03-02 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト インターロイキン−１０イムノコンジュゲート
JP7544598B2 (ja) * 2017-11-10 2024-09-03 アーモ・バイオサイエンシーズ・インコーポレイテッド 免疫チェックポイント経路阻害剤と併用したインターロイキン－１０の組成物および使用方法
CN113811549A (zh) * 2019-02-21 2021-12-17 Xencor股份有限公司 非靶向和靶向性il-10 fc融合蛋白

Also Published As

Publication number Publication date
UY39562A (es) 2022-05-31
CA3201656A1 (en) 2022-06-16
CL2023001677A1 (es) 2024-01-19
TW202237631A (zh) 2022-10-01
CR20230243A (es) 2023-07-13
EP4259644A1 (en) 2023-10-18
IL303501A (en) 2023-08-01
PE20241070A1 (es) 2024-05-13
KR20230118919A (ko) 2023-08-14
US20240034764A1 (en) 2024-02-01
AU2021398529A9 (en) 2024-10-24
MX2023006830A (es) 2023-07-06
CN117120461A (zh) 2023-11-24
JP2023553934A (ja) 2023-12-26
AU2021398529A1 (en) 2023-06-29
MA61003A1 (fr) 2023-10-31
CO2023007563A2 (es) 2023-07-21
MA61003B1 (fr) 2024-12-31
WO2022124950A1 (en) 2022-06-16
EP4259644A4 (en) 2024-10-16
ECSP23043458A (es) 2023-07-31

Similar Documents

Publication Publication Date Title
AR111207A1 (es) Anticuerpos anti-lag3
Pappu et al. The interleukin‐17 cytokine family: critical players in host defence and inflammatory diseases
DE69735376T2 (de) Fusionsproteine, die stressproteine beinhalten, zum hervorrufen einer immunantwort
PE20231439A1 (es) Proteinas f de hmpv estabilizadas por prefusion
AR123628A1 (es) Constructos anti-cd93 y usos de estos
CN100564527C (zh) A型肉毒毒素受体结合区Hc基因及其编码蛋白与应用
BRPI0815578B8 (pt) Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer)
Wang et al. Hybrid phage displaying SLAQVKYTSASSI induces protection against Candida albicans challenge in BALB/c mice
CA3085318A1 (en) Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis
JP2017511133A5 (es)
AR125379A1 (es) Un fab anti-tslp con estabilidad mejorada
WO2022043449A1 (en) Vaccines based on an antigen protein fused to a nanostructuring scaffold
CL2023001433A1 (es) Muteína de il-2; proteína de fusión; ácido nucleico; vector; célula hospedera; métodos; uso
AR124310A1 (es) INMUNOCITOQUINA PARA ACTIVAR EL RECEPTOR IL-10Ra HUMANO Y SU USO
JP2021509254A (ja) Ｈ３ｎ２亜型インフルエンザウイルスのヘマグルチニンタンパク質の突然変異体及びその使用
ECSP23034907A (es) Ácido nucleico que codifica una entidad anti–vegf y un regulador del complemento negativo y sus usos para el tratamiento de la degeneración macular relacionada con la edad
AR035077A1 (es) Polipeptidos de neublastina variante, proteinas de fusion, acidos nucleicos, vectores, celulas hospedadoras, metodos para producir dichos polipeptidos, dimeros, conjugados, composiciones farmaceuticas y uso de dichos polipeptidos en la preparacion de medicamentos
AR041086A1 (es) Vacuna
EP1492814B1 (fr) Peptide dérivé de l'interleukine-1-beta et son application thérapeutique
Hamza et al. Structural characterization and binding studies of the ectodomain g protein of respiratory syncytial virus reveal the crucial role of ph with possible implications in host–pathogen interactions
Liu et al. Intranasal Epitope‐Polymer Vaccine Lodges Resident Memory T Cells Protecting Against Influenza Virus
CR20170507A (es) Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos.
AR029168A1 (es) Una composicion acidos nucleicos peptidicos y un metodo para prepararla
White et al. Flublok Quadrivalent Vaccine Adjuvanted with R-DOTAP Elicits a Robust and Multifunctional CD4 T Cell Response That Is of Greater Magnitude and Functional Diversity Than Conventional Adjuvant Systems
RU2563989C1 (ru) Композиция для подавления экспрессии гена цитокина интерлейкина-4